Divis Laboratories Ltd Share Price Today - Divis Laboratories Ltd Live Updates NSE/BSE

NSEBSE

There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.

Max

Open9,114

High9,190

Low9,006.5

Prev. Close9,162

Avg. Traded Price9,103.22

Volume10,40,584

MARKET DEPTH

Total bid0.00

Total ask280.00

Orders	Qty	Bid
0	0	0
0	0	0
0	0	0
0	0	0
0	0	0

Ask	Qty	Orders
9162	5	280
0	0	0
0	0	0
0	0	0
0	0	0

HIGH/LOW

52w

LOW/HIGH

₹9006.509 hours ago

₹9190.009 hours ago

LOWER/UPPER CIRCUITS

₹8271.00

₹10109.00

Divis Laboratories Ltd Stock performance

KEY OBSERVATIONS

positive

negative

neutral

Annual Revenue,rose 13.95%, in the last year to ₹11,067 Cr. Its sector's average revenue growth for the last fiscal year was 12.19%.

Annual Net Profit,rose 17.21% in the last year to ₹2,568 Cr. Its sector's average net profit growth for the last fiscal year was 1.94%.

Quarterly Revenue,rose 27.8% YoY to ₹3,144 Cr. Its sector's average revenue growth YoY for the quarter was 15.56%.

LONG-TERM PRICE ANALYSIS

Stock return5Y CAGR : 15.13%

Net profit growth 5Y CAGR : 3.41%

STOCK RETURNS

Versus Nifty 50

1 w

-2.99%

+3.5%

1 mth

-2.83%

-1.15%

3 mth

+24.96%

-4.51%

6 mth

+45.61%

-5%

1 yr

+38.47%

-10.44%

3 yr

+151.38%

+17.94%

5 yr

+76.12%

+25.67%

Divis Laboratories Ltd Top mutual funds holding

HDFC Pharma and Healthcare Fund-Reg(G)

3Y Return+26.3%

NAV₹20.08

Franklin Asian Equity Fund(G)

3Y Return+20.7%

NAV₹41.46

About Divi’s Laboratories Limited

Divi’s Laboratories Limited, founded in 1990 and headquartered in Hyderabad, is one of the world’s leading manufacturers of active pharmaceutical ingredients (APIs). Its core businesses span Generic APIs, Custom Synthesis for innovator pharma companies, and Nutraceutical ingredients. Divi’s serves customers in over 100 countries, working with 12 of the world’s top 20 pharmaceutical companies.

The company is among the top three global API makers and the largest producer of 10 out of 30 APIs in its portfolio. Its nutraceuticals division manufactures carotenoids and vitamins for dietary supplements, food, beverages, pet food, and feed, with products including Beta Carotene, Astaxanthin, Lycopene, Lutein, and vitamins A, D3, and E Acetate.

Divi’s operates three large manufacturing campuses across Telangana and Andhra Pradesh, supported by three R&D centers and overseas subsidiaries in the USA (New Jersey) and Switzerland (Basel).

Divi’s Laboratories Limited’s Business Segments

Generic APIs: High-quality APIs across cardiovascular, anti-inflammatory, oncology, and CNS therapies.
Custom Synthesis: End-to-end solutions for innovator companies, from early clinical to late life-cycle stages.
Nutraceuticals: Carotenoids and vitamins tailored for supplements and food industries.

Exports accounted for 88% of FY25 revenue, reflecting Divi’s global scale.

Geographic Revenue (FY25 standalone): Europe ₹5,192 crore (56%), North America ₹1,488 crore (16%), Asia ₹1,044 crore (11%), India ₹1,105 crore (12%), Rest of World ₹367 crore (4%).

Divi’s Laboratories Limited’s Key Management

Dr. Murali K. Divi – Managing Director, leads strategy and operations.
Dr. Kiran S. Divi – Whole-time Director & CEO, oversees execution.
N. V. Ramana – Executive Director, supports business operations.

Latest Updates (FY25) on Divi’s Laboratories Limited

Capacity expansion: Began operations at Unit 3, Kakinada, on Jan 1, 2025, boosting manufacturing footprint.
Technology: Added infrastructure for peptide synthesis (solid and liquid phase).
Regulatory: Successfully cleared US FDA inspection at Unit 2.
Financials: Standalone income ₹9,550 crore; PAT ₹2,209 crore; EPS ₹83.20.
Capital investment: Deployed ₹1,118 crore into expansion, backward integration, and technology.
Dividend: Recommended ₹30 per share final dividend (record date July 25, 2025).
Credit rating: CARE reaffirmed AA+ (Stable).
Sustainability: Achieved CDP “B” rating, conserved ~34,870 GJ energy, recycled over 1.1 million KL water, and recorded ~38 million safe man-hours.

Similar stocks

SUNPHARMA₹1758.00+12.90 (0.74%)

TORNTPHARM₹4615.30+61.50 (1.35%)

ZYDUSLIFE₹1135.00+17.70 (1.58%)

LAURUSLABS₹2002.50-10.00 (0.50%)

CIPLA₹1330.90+16.90 (1.29%)

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

What is the return of Divis Laboratories Ltd in the past 5 years?

Divis Laboratories Ltd has delivered a 81.14% absolute return over the past 5 years, equivalent to a CAGR of 12.62% per annum. The stock was priced at ₹5,057.97 in Oct 2021 and has risen to ₹9,162.00 as of 22 Oct 2026. An investment of ₹1,00,000 in Divis Laboratories Ltd five years ago would be worth ₹1,81,140.00 today.

Has Divis Laboratories Ltd offered any dividend in the past 5 years?

Yes,Divis Laboratories Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 150.00 per share between FY2022 and FY2026, with the most recent dividend of ₹30.00 per share for May 26, with an ex-dividend date of 24 Jul 2026. At the current market price of ₹9,162.00, the trailing dividend yield of Divis Laboratories Ltd stands at 60.00%.

How much return has Divis Laboratories Ltd given in the last 3 months?

Divis Laboratories Ltd has delivered a return of 24.42% over the last 3 months. The stock was trading at ₹7,386.50 on 22 Jul 2026 and is currently at ₹9,162.00 as of 22 Oct 2026, reflecting a Gain of ₹1775.50 per share over this period.

What is the share price of Divis Laboratories Ltd?

As of 22 Oct 2026, the share price of Divis Laboratories Ltd is ₹9,162.00 on the NSE and ₹9,116.00 on the BSE. The stock opened at ₹9,190.00, touched a high of ₹9,190.00 and a low of ₹9,006.50 during today's session.

How much return has Divis Laboratories Ltd given in the last 6 months?

Over the last 6 months, Divis Laboratories Ltd has given a return of 46.21%. The stock was priced at ₹6,285.50 on 22 Apr 2026 and has Rise to ₹9,162.00 as of 22 Oct 2026, a change of ₹2876.50 per share.

What was today's high for Divis Laboratories Ltd share?

The intraday high for Divis Laboratories Ltd on the NSE today (22 Oct 2026) was ₹9,190.00. This compares to the 52-week high of ₹9,740.00 recorded on 24 Sep 2026. Today's high was -5.65% below the 52-week high.

What were the most recent reported sales and net income of Divis Laboratories Ltd?

For Q1 FY27, Divis Laboratories Ltd reported: Revenue (Net Sales): ₹29740.00 Cr - Up 6.48% year-on-year from ₹27930.00 Cr in Q4 FY26. Net Income (PAT): ₹8910.00 Cr - Up 17.86% year-on-year from ₹7560.00 Cr in Q4 FY26.

How much return has Divis Laboratories Ltd given in the last 52 weeks?

Divis Laboratories Ltd has delivered 39.97% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹9,740.00 on 24 Sep 2026 and a 52-week low of ₹5,647.50 on 02 Apr 2026. It is currently trading at ₹9,162.00 as of 22 Oct 2026.

What is the highest Divis Laboratories Ltd share price ever recorded and when?

The all-time high (ATH) for Divis Laboratories Ltd was ₹9,624.00, recorded on 23 Sep 2026. At the current price of ₹9,162.00, the stock is trading 4.80% below its all-time high. The all-time low recorded was ₹282.60 on 05 Feb 2010.

What was Divis Laboratories Ltd's low today on the NSE?

The intraday low for Divis Laboratories Ltd on the NSE today was ₹9,006.50. The stock's 52-week low stands at ₹5,647.50, recorded on 02 Apr 2026. Today's low is 59.48% above the 52-week low, indicating the stock is trading well above its yearly lows.